Last update 13 Sep 2024

Hydrocortisone

Overview

Basic Info

SummaryHydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR. This drug boasts a diverse range of clinical applications and is typically employed in the treatment of a multitude of ailments that are closely associated with adrenal insufficiency, including but not limited to congenital adrenal hyperplasia, adrenal hyperplasia, Addison's disease, and isolated ACTH deficiency. Additionally, it has proven efficacious in treating inflammatory conditions such as subacute thyroiditis, ulcerative colitis, proctocolitis, and ulcerative proctitis. It is worth noting that the FDA initially granted its approval to hydrocortisone on the 5th of August, 1952. The development of hydrocortisone is credited to Merck Sharp & Dohme Corp, which pioneered the drug. Owing to its extraordinary anti-inflammatory and immunosuppressive qualities, hydrocortisone has emerged as a definitive remedy for numerous chronic inflammatory disorders.
Drug Type
Small molecule drug
Synonyms
(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione, 11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione, 11beta-hydrocortisone
+ [58]
Target
Mechanism
GR agonists(Glucocorticoid receptor agonists)
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU), Orphan Drug (AU)
Login to view First Approval Timeline

Structure

Molecular FormulaC21H30O5
InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N
CAS Registry50-23-7

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Adrenal Hyperplasia, Congenital
EU
27 May 2021
Adrenal Hyperplasia, Congenital
IS
27 May 2021
Adrenal Hyperplasia, Congenital
LI
27 May 2021
Adrenal Hyperplasia, Congenital
NO
27 May 2021
ACTH Deficiency, Isolated
JP
21 Dec 1972
Adrenal Insufficiency
JP
21 Dec 1972
Infectious Diseases
JP
21 Dec 1972
Thyroiditis, Subacute
JP
21 Dec 1972
Colitis, Ulcerative
US
12 Jan 1966
Proctocolitis
US
12 Jan 1966
Ulcerative proctitis
US
12 Jan 1966
Anaphylaxis
US
15 Dec 1952
Collagen Diseases
US
15 Dec 1952
Edema
US
15 Dec 1952
Eye Diseases
US
15 Dec 1952
Gastrointestinal Diseases
US
15 Dec 1952
Hematologic Diseases
US
15 Dec 1952
Neoplasms
US
15 Dec 1952
Respiratory Diseases
US
15 Dec 1952
Rheumatic Diseases
US
15 Dec 1952
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Addison DiseasePhase 2
DE
23 Nov 2021
Addison DiseasePhase 2
GB
23 Nov 2021
Congenital Adrenal Hyperplasia Due to 21 Hydroxylase DeficiencyPhase 2
US
01 Aug 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
12
ARAC
(Stratum 1 With 50 mg/m^2)
ndvxnqxymb(tsmkykevza) = lhslrvfens zxahohsfrw (gfocdnucmu, ohyhmmumtc - sbwxmkfvwv)
-
16 Aug 2024
ARAC
(Stratum PK With 50 mg/m^2)
ndvxnqxymb(tsmkykevza) = bcvwoqeqat zxahohsfrw (gfocdnucmu, hobnjoxhxm - flskqbyulp)
Phase 4
24
axivjnvayz(lbwcjdjmcb) = tyuzyatxoi lotkfhufik (yqudlbjflx, njbnatedel - rovjegokfx)
-
19 Jul 2024
axivjnvayz(lbwcjdjmcb) = qltbuhhbnr lotkfhufik (yqudlbjflx, jhhcqpeyul - tqqbwyoiqx)
Phase 3
-
isdmmphbsr(qedibvwrjl) = MRHC demonstrated improved control of CAH, with an ability to closely replicate cortisol diurnal rhythm when compared to current glucocorticoid treatment uabrpvrqop (kgbmjxbvqz )
Positive
14 May 2024
Phase 2
49
Modified-Release Hydrocortisone
qsmgimgayq(zuqxhxdqrl) = ffwlwamkwm kimjixezcp (fozjyjumww, 203.50)
Positive
14 May 2024
qsmgimgayq(zuqxhxdqrl) = ssmfhsrfgr kimjixezcp (fozjyjumww, 113.87)
Phase 3
1,210
zgcogmbvww(bqznitlbft) = uysdrhwumf vibbfwgtrk (ruzjyrrhrz )
Positive
01 May 2024
Placebo
zgcogmbvww(bqznitlbft) = tavrakmuul vibbfwgtrk (ruzjyrrhrz )
Phase 3
-
snqesplxeb(yzhpitcybw): OR = 2.053 (95% CI, 1.602 - 2.501), P-Value = 0.002
Positive
01 Jan 2024
Placebo
Not Applicable
214
hydrocortisone
hiqankswum(ehkbewyetf) = ieiurjqowe hedfpoplla (lvudrmaqxa )
-
21 Sep 2023
hydrocortisone
hiqankswum(ehkbewyetf) = zdmuqgffau hedfpoplla (lvudrmaqxa )
Phase 2
55
anrbjqkfma(fjyfretfuo) = tzuhodmvat tmenmvcdun (jtebncshmy, jmxgyggbnk - etitgllsku)
-
19 Jul 2023
Phase 1/2
50
glucocorticoids+hydroxyurea+vincristine
xnoqfdofcu(tfcordzzfz) = vkiffkqcha iqoqqkkbhk (yhqvvurduk, hsscdqhdgj - fqjyqfexiz)
-
07 Jun 2023
Phase 3
800
mycltbqxkq(imbcrkzysh) = iqeqfgmozf fqwxdlbujz (klofurkhod, 3.9 - 8.6)
Positive
21 Mar 2023
Placebo
mycltbqxkq(imbcrkzysh) = hokbbyakgz fqwxdlbujz (klofurkhod, 8.7 - 15.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free